Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alerus Financial Corp

Algonquin Power & Utilities

Curtiss-Wright

First Merchants

Gaming and Leisure Properties

Houlihan Lokey

Microchip Technology

Phillips 66

SPDR S&P 500 ETF Trust

Union Pacific

This article series covers dividend increases, cuts, and suspensions. We provide a summary table of relevant data and key statistics on dividend increases.

Dividend Increases: May 7-13, 2022

AbbVie

Amcor Plc

Chevron

Exxon Mobil

These 7 high-yield retirement stocks to buy are among a list of companies that are dividend aristocrats and offer great dividends. The post 7 High-Yield Retirement Stocks to Buy for Your Nest Egg appeared first on InvestorPlace.

7 High-Yield Retirement Stocks to Buy for Your Nest Egg

Altice USA

Crocs

Dell Technologies

HF Sinclair Corp

AXA Equitable Holdings Inc

Western Digital

These beaten-down growth stocks look like big bargains as they are now heavily oversold despite their reassuring prospects. The post 7 Beaten-Down Growth Stocks That Look Like Big Bargains Right Now appeared first on InvestorPlace.

7 Beaten-Down Growth Stocks That Look Like Big Bargains Right Now

Nordstrom

Nordstrom Breaks Retail's Losing Streak, But This Stock Just Broke a Cardinal Rule

Kimberly-Clark

Lumen Technologies

Magellan Midstream Partners

Altria

Medical Properties Trust

Highest-yielding dividend stocks offer add stability and consistent returns to portfolios The post The 7 Highest-Yielding Dividend Stocks to Buy Now for Income appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

The 7 Highest-Yielding Dividend Stocks to Buy Now for Income

Atmos Energy

Chubb

Colgate-Palmolive

Hormel Foods

McDonald's

PepsiCo

Despite the way the financial news talking heads try to spin it, and Wall Street firms projecting that a recession is likely 12 to 24 months from now, we are teetering on one right now.

8 ‘Strong Buy' Dividend Aristocrats Will Hold Up in the Coming Recession

Enbridge

These stocks pay generous dividends, and their payouts have been rising for decades.

2 High-Yielding Dividend Stocks to Power Up Your Passive Income

Medical retailer Cardinal Health Inc (NYSE:CAH) is eyeing relatively modest losses today, considering the severity of the broader market's selloff.

Healthcare Stock to Target as the Broader Market Plummets

DUBLIN, Ohio , May 10, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.4957 per share out of the Company's capital surplus. The dividend will be payable on July 15, 2022 to shareholders of record at the close of business on July 1, 2022.

Cardinal Health Raises Quarterly Dividend

Align Technology

Becton, Dickinson and Co.

Henry Schein

McKesson

Patterson Companies

SmileDirectClub

Although Covid-19 allowed people the excuse to not see their dentist, the necessary return could benefit these dental stocks to buy. The post 7 Stock Picks to Play the Post-Pandemic Return of Dental Visits appeared first on InvestorPlace.

7 Stock Picks to Play the Post-Pandemic Return of Dental Visits

An extended agreement with a leading pharmacy has boosted investor confidence.

This 1 Healthcare Dividend Stock Has Risen While Others Struggle

Cardinal Health's (CAH) fiscal third-quarter results benefit from a solid performance in the Pharmaceutical segment.

Cardinal Health (CAH) Q3 Earnings Lag Estimates, Revenues Top

Cardinal Health Inc (NYSE: CAH) has reported Q3 FY22 adjusted EPS of $1.45, down 5% Y/Y, missing the consensus of $1.52 Q2 sales increased 14% Y/Y to $44.8 billion, beating the consensus estimate of $43.16 billion. The pharmaceutical segment increased 17% to $41 billion, driven primarily.

Cardinal Health's Shares Fall as Inflation and Supply Chain Constraints Hit Q3 Earnings

Cardinal Health, Inc. (NYSE:CAH ) Q3 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Kevin Moran - Vice President, Investor Relations Mike Kaufmann - Chief Executive Officer Jason Hollar - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen Eric Percher - Nephron Research Michael Cherny - Bank of America Lisa Gill - JPMorgan Ricky Goldwasser - Morgan Stanley Elizabeth Anderson - Evercore ISI George Hill - Deutsche Bank AJ Rice - Credit Suisse Eric Coldwell - Baird Steven Valiquette - Barclays Operator Good day and welcome to the Cardinal Health, Inc. Third Quarter Fiscal Year 2022 Earnings Conference Call. Today's conference is being recorded.

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q3 2022 Results - Earnings Call Transcript

Cardinal (CAH) delivered earnings and revenue surprises of -5.84% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q3 Earnings Miss Estimates

Shares of Cardinal Health Inc. CAH, +2.89% tumbled 6.0% in premarket trading on Thursday after the medical and pharmaceutical distributor missed on earnings for the quarter. Cardinal Health had a net loss of $1.4 billion, or $5.05 per share, in its third quarter of 2022, after net income of $119 million, or 40 cents per share, in the same quarter a year ago.

Cardinal Health's stock falls 6% after earnings miss

Revenue increased 14% to $44.8 billion GAAP 1 operating loss was $97 million due to a non-cash, pre-tax goodwill impairment of $474 million in the Medical segment; GAAP diluted loss per share was $5.05, primarily due to this impairment, net of tax effects Non-GAAP operating earnings decreased 21% to $545 million, primarily due to a decline in Medical segment profit; Non-GAAP diluted EPS decreased 5% to $1.45 Finalized the previously announced national opioid settlement agreement Company updates FY22 guidance DUBLIN, Ohio , May 5, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2022 revenues of $44.8 billion, an increase of 14% from the third quarter of last year. Third quarter GAAP operating loss was $97 million, due to a non-cash, pre-tax goodwill impairment of $474 million in the Medical segment.

Cardinal Health Reports Third Quarter Fiscal 2022 Results

Insulet

The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.

Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD

Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?

AmerisourceBergen

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas--(BUSINESS WIRE)--AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have reached an agreement with the Washington Attorney General, under which the distributors will pay up to $518 million to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with Washington's allocation under the previously announced comprehensive agree

Distributors Agree to Opioid Settlement With Washington State

DUBLIN, Ohio , April 27, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the winners and honorees of its annual Lab Excellence List, which names top clinical laboratory professionals making significant contributions to health care and patient outcomes through their research, diagnosis, innovation or advocacy. The list is part of celebrations surrounding the industry's annual Medical Laboratory Professionals Week, a more than 40-year-long tradition that celebrates lab professionals across all of health care.

Cardinal Health honors top clinical laboratory professionals

Essex Property Trust

Coca-Cola

Realty Income Corp

Walmart

Even though some early first-quarter earnings have come in very solid, the reality is the market is teetering and could be ready to plunge.

8 ‘Strong Buy' Rated Dividend Aristocrats to Buy Now in Case of a Total Market Collapse

Clorox

These are great places to park your money for the long haul.

Got $5,000? These 2 Aristocrats Are Paying More Than Double the S&P 500 Average

DUBLIN, Ohio , April 1, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2022 on May 5 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2022 on May 5

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.

Cardinal Health (CAH) to Extend Medical Distribution Presence

News for Cardinal Health Stock (CAH)